Rebranded from Kapil Cotex Limited to Skybiotech Healthcare Limited effective 7 November 2025, with its Corporate Identification Number reclassified from L17100 (textiles) to L21001 (pharmaceuticals and healthcare), reflecting a stated pivot into healthcare. On a standalone basis, the original textile business is effectively dormant: standalone revenue from operations was just Rs 1.54 lakh in Q2 FY26 and zero in Q3 FY26. The actual activity sits in subsidiary Skybiotech Life Sciences Pvt Ltd, which contributed Rs 733.69 lakh of income but a loss of Rs 105.72 lakh in FY26. Consolidated FY26 revenue from operations was Rs 709.78 lakh (up 0.65% YoY), with a consolidated net loss of Rs 111.68 lakh, narrower than the Rs 236.89 lakh loss in FY25. Quarterly trends are choppy — consolidated Q2 FY26 revenue of Rs 191.65 lakh collapsed to Rs 96.27 lakh in Q3 FY26. Materials make up 43.6% of revenue, employees 24.8%, and other operating expenses 40.8%. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Healthcare / life sciences (via subsidiary Skybiotech Life Sciences Pvt Ltd), Legacy textiles (standalone). Small BSE-listed shell that has rebranded from textiles to healthcare; revenue is concentrated in a single loss-making subsidiary and has been choppy across recent quarters.
| ₹ crore · consolidated | FY25 | FY26 |
|---|---|---|
| Revenue | 7 | 7 |
| EBITDA (ex other income) | (2) | (1) |
| margin % | (32.0) | (20.8) |
| Owners' profit | 0 | (1) |
| EPS, as reported (₹) | 14.19 | 6.70 |
| ROE % · ROCE % | (22.5) · (13.8) | (12.1) · (9.4) |
| Debt / equity (x) | 0.68 | 0.91 |
| Cash from operations | (1) | (2) |
| Capex | 0 | (0) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 2 | 3 | 1 | 2 | 2 | 1 | 2 |
| Profit before tax | (0) | (0) | (0) | (1) | (0) | (0) | (0) | (1) |
| Net profit | (0) | (0) | (0) | (1) | (0) | (0) | (0) | (0) |
| EPS (₹) | 0.25 | 5.46 | (3.06) | 13.68 | 0.25 | 1.29 | 1.29 | 2.96 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| KPR MILL LTD. | 37,974 | 41.6 | 6.66 | 27.5 | 15.2 | 19.3 | 13.5 | 21.2 |
| WELSPUN LIVING LIMITED | 19,663 | 71.5 | 3.95 | 25.3 | 4.3 | 4.0 | 5.1 | 12.7 |
| VARDHMAN TEXTILES LIMITED | 16,368 | 19.0 | 1.55 | 12.4 | 7.1 | 7.4 | 10.0 | 20.4 |
| TRIDENT LIMITED | 11,965 | 30.1 | 2.51 | 14.5 | 7.9 | 8.6 | 8.1 | 17.7 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 5 Sept 2026 · Notice of 43rd AGM on September 30, 2026 | board shareholder meetings | low | — | — |
| 5 Sept 2026 · FY26 Annual Report filed; pharma pivot, losses persist | general | low | — | — |
| 11 Aug 2026 · Board Meeting on 14 Aug 2026 to consider Q1 FY27 results | results | low | — | — |
| 19 Jul 2026 · Compliance Certificate under Reg 74(5) for Q1 FY27 | compliance | minimal | — | — |
| 27 Jun 2026 · Trading Window Closure from 1 July 2026 for Q1 FY27 Results | compliance | minimal | — | — |
| 30 May 2026 · Submission of Financial Results for the Quarter and Year ended on 31st March 2026 | results | high | — | — |
| 30 May 2026 · Submission of Outcome of board meeting and Financial Results for the quarter and year ended on 31st March 2026 | results | high | — | — |
| 26 May 2026 · Skybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Approval of Audited Results .... | results | low | — | — |
| 30 Apr 2026 · <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... | compliance | minimal | — | — |
| 9 Apr 2026 · Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018 received from RTA | compliance | minimal | — | — |
| INDO COUNT INDUSTRIES LTD | 8,757 | 58.0 | 3.72 | 21.1 | 5.4 | 5.4 | 10.5 | 13.3 |
| GARWARE TECH FIBRES LTD | 7,675 | 37.1 | 5.67 | 24.0 | 14.7 | 18.7 | 8.1 | 20.5 |
| JINDAL WORLDWIDE LTD | 5,314 | 63.1 | 6.17 | 40.6 | 8.1 | 9.0 | 6.1 | 8.7 |
| RAYMOND LIFESTYLE LIMITED | 4,213 | 97.2 | 0.44 | 7.7 | 0.5 | 0.7 | — | 8.9 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 20.9 | 14.8 | 126 of 205 | 39% |
| P/B | 2.5 | 1.3 | 141 of 183 | 23% |
| ROCE | (9.5) | 4.2 | 206 of 227 | 9% |
| ROE | (12.1) | 4.8 | 201 of 214 | 6% |
| Debt / Equity | 0.9 | 0.3 | 166 of 214 | 23% |
| EBITDA margin | (39.7) | 9.8 | 193 of 198 | 3% |
| Revenue growth | 79.7 | 6.9 | 25 of 192 | 87% |
| Profit growth | 72.0 | 20.0 | 69 of 203 | 66% |
| Market cap | 23 | 63 | 161 of 221 | 27% |
| Where a broker report shows | This document shows | Why |
|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
